New drugs for tuberculosis treatment

Tuberculosis (TB) is a significant global health problem, and the development of new drugs is crucial to combat the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Here are some new drugs and treatment regimens being developed or recently approved for TB treatment:

1. Bedaquiline (Sirturo): Approved in 2012, bedaquiline is a diarylquinoline that targets the bacterial protein ATP synthase. It is used in combination with other drugs to treat MDR-TB.
2. Delamanid (Deltyba): Approved in 2014, delamanid is a nitroimidazole that targets the bacterial protein DNA gyrase. It is used in combination with other drugs to treat MDR-TB.
3. Linezolid (Zyvox): While not specifically approved for TB, linezolid is sometimes used off-label to treat MDR-TB, particularly in combination with other drugs.
4. Pretomanid (Pa-824): A nitroimidazole in development, pretomanid has shown promising results in clinical trials for the treatment of MDR-TB.
5. TMC-207 (Bedaquiline): A diarylquinoline in development, TMC-207 has shown similar efficacy to bedaquiline in clinical trials.
6. SQ109: A novel antibiotic in development, SQ109 has shown activity against M. tuberculosis and is being evaluated as a potential treatment for MDR-TB.
7. PA-824: A nitroimidazole in development, PA-824 has shown promising results in clinical trials for the treatment of MDR-TB.
8. OZ-100: A novel antibiotic in development, OZ-100 has shown activity against M. tuberculosis and is being evaluated as a potential treatment for MDR-TB.
9. Nitroimidazoles: A class of antibiotics in development, nitroimidazoles have shown promising results in clinical trials for the treatment of MDR-TB.
10. New regimens: Researchers are exploring new treatment regimens that combine existing and new drugs to improve treatment outcomes and reduce the risk of resistance.

Some notable clinical trials and studies include:

• The TB Alliance's Phase III trial of pretomanid, bedaquiline, and linezolid for the treatment of MDR-TB.
• The NIAID's Phase II trial of SQ109 for the treatment of MDR-TB.
• The TB Alliance's Phase II trial of OZ-100 for the treatment of MDR-TB.
• The WHO's Global TB Programme's efforts to develop and evaluate new TB treatment regimens.

These new drugs and treatment regimens offer hope for improving TB treatment outcomes and reducing the global burden of this disease.